Filing Flows › Haemonetics (HAE) › How it makes money
How Haemonetics (HAE) makes money
Haemonetics (HAE) made $358M of revenue in the second quarter fiscal 2027 (Q2 FY27), +9% from a year earlier. Apheresis brought in $205M (57%); MedSurg brought in $153M (43%). Of every dollar of revenue, 62¢ was left as gross profit, 21¢ was left as operating profit, 13¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q2 FY27
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Apheresis | $205M | 57.2% | +7% | +13% |
| MedSurg | $153M | 42.8% | +3% | +5% |
Where each dollar of revenue goes
| Line | Q2 FY27 | % of revenue |
|---|---|---|
| Revenue | $358M | 100.0% |
| Cost of revenue | $137M | 38.3% |
| Gross profit | $221M | 61.7% |
| Operating expenses | $146M | 40.8% |
| Operating profit | $75.1M | 21.0% |
| Income tax | $16.6M | 4.6% |
| Net earnings | $46.3M | 12.9% |
| Operating cash flow | $128M | 35.8% |
| Free cash flow | $113M | 31.7% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 FY27 | $358M | +9% |
| Q1 FY27 | $339M | +6% |
| Q4 FY26 | $346M | +5% |
| Q3 FY26 | $339M | -3% |
| Q2 FY26 | $327M | -5% |
| Q1 FY26 | $321M | -4% |
| Q4 FY25 | $331M | -4% |
From Haemonetics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Haemonetics make money?
Haemonetics (HAE) made $358M of revenue in the second quarter fiscal 2027 (Q2 FY27), +9% from a year earlier. Apheresis brought in $205M (57%); MedSurg brought in $153M (43%). Of every dollar of revenue, 62¢ was left as gross profit, 21¢ was left as operating profit, 13¢ was left as net earnings.
What is Haemonetics' biggest business?
Apheresis: $205M in the second quarter fiscal 2027, 57% of revenue, +13% from a year earlier.
What is Haemonetics' profit margin?
Net earnings were $46.3M, 12.9% of revenue, in the second quarter fiscal 2027; the operating margin was 21.0%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.